Skip to main content

Advertisement

SpringerLink
Log in

Intragastric Balloon in Association with Lifestyle and/or Pharmacotherapy in the Long-Term Management of Obesity

  • Clinical Research
  • Published:
Obesity Surgery Aims and scope Submit manuscript

Abstract

Background

Intragastric balloon (BioEnterics Intragastric Balloon, BIB®) or pharmacotherapy are possible options for the treatment of obese patients when traditional approaches have failed. The aim of our study was to compare in obese patients the effect on weight loss and metabolic changes of lifestyle modifications associated with either BIB or pharmacotherapy or the two treatments in sequence as a maintenance strategy for weight loss.

Methods

Fifty obese patients were recruited and randomly assigned to lifestyle modifications combined with either BIB for 6 months (n = 30) or sibutramine (pharmacotherapy group) for 1 year (n = 20). After BIB removal, patients were randomly assigned to either correct lifestyle (BIB/lifestyle) or lifestyle plus pharmacotherapy (BIB/pharmacotherapy).

Results

At 6 months, patients treated with BIB lost significantly (P < 0.05) more weight (percent of initial weight lost, %IWL = 14.5 ± 1.2; percent of excess BMI lost, %EBL = 37.7 ± 3.2) than patients who received pharmacological treatment (%IWL = 9.1 ± 1.5, %EBL = 25.3 ± 4.1). At 1 year, the weight lost was significantly (P < 0.05) greater in patients treated with either BIB/pharmacotherapy (%IWL = 15.8 ± 2.3%, %EBL = 41.3 ± 6.7%) or BIB/lifestyle (%IWL = 14.3 ± 2.7, %EBL = 34.9 ± 6.5%) in respect to pharmacotherapy group (%IWL = 8.0 ± 1.4%, %EBL = 22.1 ± 3.9%). Moreover, patients treated sequentially with BIB/lifestyle or BIB/pharmacotherapy showed a significant (P < 0.05) improvement in insulin sensitivity and triglycerides levels.

Conclusions

BIB represents an efficacious long-term obesity treatment when supplemental strategies, as lifestyle modifications or pharmacotherapy, are established for weight maintenance after its removal.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Despres JP, Pascot A, Lemieux I. Risk factors associated with obesity: a metabolic perspective. Ann Endocrinol (Paris). 2000;61 Suppl 6:31–8.

    CAS  Google Scholar 

  2. Vigneri P, Frasca F, Sciacca L, et al. Obesity and cancer. Nutr Metab Cardiovasc Dis. 2006;16(1):1–7.

    Article  PubMed  CAS  Google Scholar 

  3. Adams KF, Schatzkin A, Harris TB, et al. Overweight, obesity, and mortality in a large prospective cohort of persons 50 to 71 years old. N Engl J Med. 2006;355(8):763–78.

    Article  PubMed  CAS  Google Scholar 

  4. Overweight, obesity, and health risk. National Task Force on the Prevention and Treatment of Obesity. Arch Intern Med 2000;160(7):898–904.

    Google Scholar 

  5. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults-The Evidence Report. National Institutes of Health. Obes Res 1998; 6 Suppl 2:51S–209S.

  6. Horton ES. Effects of lifestyle changes to reduce risks of diabetes and associated cardiovascular risks: results from large scale efficacy trials. Obesity (Silver Spring). 2009;17 Suppl 3:S43–8.

    Article  Google Scholar 

  7. Long SD, O'Brien K, MacDonald KG, et al. Weight loss in severely obese subjects prevents the progression of impaired glucose tolerance to type II diabetes. A longitudinal interventional study. Diabetes Care. 1994;17(5):372–5.

    Article  PubMed  CAS  Google Scholar 

  8. Despres JP, Lemieux I, Prud'homme D. Treatment of obesity: need to focus on high risk abdominally obese patients. BMJ. 2001;322(7288):716–20.

    Article  PubMed  CAS  Google Scholar 

  9. Wing RR. Use of very-low-calorie diets in the treatment of obese persons with non-insulin-dependent diabetes mellitus. J Am Diet Assoc. 1995;95(5):569–72.

    Article  PubMed  CAS  Google Scholar 

  10. Doldi SB, Micheletto G, Perrini MN, et al. Intragastric balloon: another option for treatment of obesity and morbid obesity. Hepatogastroenterology. 2004;51(55):294–7.

    PubMed  CAS  Google Scholar 

  11. Imaz I, Martinez-Cervell C, Garcia-Alvarez EE, et al. Safety and effectiveness of the intragastric balloon for obesity. A meta-analysis. Obes Surg. 2008;18(7):841–6.

    Article  PubMed  Google Scholar 

  12. Forlano R, Ippolito AM, Iacobellis A, et al. Effect of the BioEnterics intragastric balloon on weight, insulin resistance, and liver steatosis in obese patients. Gastrointest Endosc. 2010;71(6):927–33.

    Article  PubMed  Google Scholar 

  13. Dumonceau JM. Evidence-based review of the Bioenterics intragastric balloon for weight loss. Obes Surg. 2008;18(12):1611–7.

    Article  PubMed  Google Scholar 

  14. Busetto L, Segato G, De Luca M, et al. Preoperative weight loss by intragastric balloon in super-obese patients treated with laparoscopic gastric banding: a case–control study. Obes Surg. 2004;14(5):671–6.

    Article  PubMed  Google Scholar 

  15. Angrisani L, Lorenzo M, Borrelli V, et al. Is bariatric surgery necessary after intragastric balloon treatment? Obes Surg. 2006;16(9):1135–7.

    Article  PubMed  Google Scholar 

  16. Frutos MD, Morales MD, Lujan J, et al. Intragastric balloon reduces liver volume in super-obese patients, facilitating subsequent laparoscopic gastric bypass. Obes Surg. 2007;17(2):150–4.

    Article  PubMed  Google Scholar 

  17. Roman S, Napoleon B, Mion F, et al. Intragastric balloon for “non-morbid” obesity: a retrospective evaluation of tolerance and efficacy. Obes Surg. 2004;14(4):539–44.

    Article  PubMed  Google Scholar 

  18. Herve J, Wahlen CH, Schaeken A, et al. What becomes of patients 1 year after the intragastric balloon has been removed? Obes Surg. 2005;15(6):864–70.

    Article  PubMed  CAS  Google Scholar 

  19. Genco A, Bruni T, Doldi SB, et al. BioEnterics intragastric balloon: the Italian experience with 2,515 patients. Obes Surg. 2005;15(8):1161–4.

    Article  PubMed  CAS  Google Scholar 

  20. Genco A, Cipriano M, Bacci V, et al. Intragastric balloon followed by diet vs intragastric balloon followed by another balloon: a prospective study on 100 patients. Obes Surg. 2010;20(11):1496–500.

    Article  PubMed  Google Scholar 

  21. Lopez-Nava G, Rubio MA, Prados S, et al. BioEnterics intragastric balloon (BIB). Single ambulatory center Spanish experience with 714 consecutive patients treated with one or two consecutive balloons. Obes Surg. 2011;21(1):5–9.

    Article  PubMed  Google Scholar 

  22. Crea N, Pata G, Della Casa D, et al. Improvement of metabolic syndrome following intragastric balloon: 1 year follow-up analysis. Obes Surg. 2009;19(8):1084–8.

    Article  PubMed  Google Scholar 

  23. Genco A, Balducci S, Bacci V, et al. Intragastric balloon or diet alone? A retrospective evaluation. Obes Surg. 2008;18(8):989–92.

    Article  PubMed  Google Scholar 

  24. Mathus-Vliegen EM. Intragastric balloon treatment for obesity: what does it really offer? Dig Dis. 2008;26(1):40–4.

    Article  PubMed  Google Scholar 

  25. Ganesh R, Rao AD, Baladas HG, et al. The Bioenteric Intragastric Balloon (BIB) as a treatment for obesity: poor results in Asian patients. Singapore Med J. 2007;48(3):227–31.

    PubMed  CAS  Google Scholar 

  26. Dastis NS, Francois E, Deviere J, et al. Intragastric balloon for weight loss: results in 100 individuals followed for at least 2.5 years. Endoscopy. 2009;41(7):575–80.

    Article  PubMed  Google Scholar 

  27. James WP, Caterson ID, Coutinho W, et al. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med. 2010;363(10):905–17.

    Article  PubMed  CAS  Google Scholar 

  28. Deitel M, Gawdat K, Melissas J. Reporting weight loss 2007. Obes Surg. 2007;17(5):565–8.

    Article  PubMed  Google Scholar 

  29. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care. 1999;22(9):1462–70.

    Article  PubMed  CAS  Google Scholar 

  30. Vetter ML, Faulconbridge LF, Webb VL, et al. Behavioral and pharmacologic therapies for obesity. Nat Rev Endocrinol. 2010;6(10):578–88.

    PubMed  CAS  Google Scholar 

Download references

Conflict of Interest

The authors (MGF, RB, AN, FV, CP, RS, CV, RV, and LF) declare no conflict of interest with any institution or product mentioned in the manuscript.

Author information

Authors and Affiliations

  1. Endocrinology Unit, Department of Clinical and Molecular Biomedicine, University of Catania Medical School, Catania, Italy

    Maria Grazia Farina, Roberto Baratta, Angela Nigro, Federica Vinciguerra, Concetta Puglisi, Roberto Schembri, Riccardo Vigneri & Lucia Frittitta

  2. Gastroenterology Unit, Garibaldi Hospital, Catania, Italy

    Clara Virgilio

  3. Endocrinology, University of Catania, Garibaldi Hospital, Via Palermo 636, 95122, Catania, Italy

    Lucia Frittitta

Authors
  1. Maria Grazia Farina
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Roberto Baratta
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Angela Nigro
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Federica Vinciguerra
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Concetta Puglisi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Roberto Schembri
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Clara Virgilio
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Riccardo Vigneri
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Lucia Frittitta
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lucia Frittitta.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Farina, M.G., Baratta, R., Nigro, A. et al. Intragastric Balloon in Association with Lifestyle and/or Pharmacotherapy in the Long-Term Management of Obesity. OBES SURG 22, 565–571 (2012). https://doi.org/10.1007/s11695-011-0514-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11695-011-0514-y

Keywords

Search

Navigation